v3.25.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash flows from operating activities:    
Net loss $ (6,105,887) $ (2,853,806)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 20,783 705,770
Depreciation 30,758
Inducement expense 2,567,044
Change in fair value of derivative instrument-warrants 4,800,481 (1,160,652)
Change in fair value of contingent consideration (770,000)
Changes in operating assets and liabilities:    
Accounts payable and accrued expenses 165,860 (2,497,276)
Right of use asset 30,859
Operating lease liability (33,752)
Prepaid expenses and other assets 1,341 364,262
Net cash used in operating activities (1,117,422) (3,616,793)
Cash flows from investing activities:    
Net cash used in investing activities
Cash flows from financing activities:    
Proceeds from the issuance of common stock and warrants, net 9,000,000 1,849,707
Equity issuance costs (802,597)
Payments on notes payable (2,900,000)
Net cash provided by financing activities 5,297,403 1,849,707
Effect of exchange rates on cash 86,708
Net increase (decrease) in cash 4,179,981 (1,680,378)
Cash at beginning of period 406,408 14,785,880
Cash at end of period 4,586,389 13,105,502
Supplementary disclosure of non-cash financing activities:    
Issuance of Note Payable for payment of prepaid expense 526,178
Inducement expense for issuance of Series B-1 and B-2 warrants 2,821,399
Cashless Exercise of 2025 Series B Warrants $ 9,757,914